Keel Point LLC Holds Position in Amgen Inc. (NASDAQ:AMGN)
Keel Point LLC maintained its stake in shares of Amgen Inc. (NASDAQ:AMGN) during the first quarter, Holdings Channel reports. The fund owned 3,466 shares of the medical research company’s stock at the end of the first quarter. Keel Point LLC’s holdings in Amgen were worth $569,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in AMGN. Jackson Grant Investment Advisers Inc. increased its stake in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the period. First Command Financial Services Inc. increased its stake in shares of Amgen by 1.1% in the first quarter. First Command Financial Services Inc. now owns 1,547 shares of the medical research company’s stock valued at $254,000 after buying an additional 17 shares during the period. Cribstone Capital Management LLC increased its stake in shares of Amgen by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 1,113 shares of the medical research company’s stock valued at $182,000 after buying an additional 25 shares during the period. Cable Hill Partners LLC increased its stake in shares of Amgen by 2.7% in the first quarter. Cable Hill Partners LLC now owns 982 shares of the medical research company’s stock valued at $161,000 after buying an additional 26 shares during the period. Finally, Howe & Rusling Inc. increased its stake in shares of Amgen by 1.1% in the first quarter. Howe & Rusling Inc. now owns 2,956 shares of the medical research company’s stock valued at $485,000 after buying an additional 31 shares during the period. Hedge funds and other institutional investors own 79.53% of the company’s stock.
Amgen Inc. (NASDAQ AMGN) traded up 0.19% during midday trading on Friday, hitting $169.43. The stock had a trading volume of 1,571,584 shares. The company has a 50-day moving average price of $174.48 and a 200-day moving average price of $167.49. The stock has a market cap of $123.63 billion, a P/E ratio of 15.43 and a beta of 1.35. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $184.21.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.84 EPS. Equities analysts expect that Amgen Inc. will post $12.57 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be paid a dividend of $1.15 per share. The ex-dividend date is Tuesday, August 15th. This represents a $4.60 annualized dividend and a dividend yield of 2.71%. Amgen’s payout ratio is 41.93%.
TRADEMARK VIOLATION WARNING: This story was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.dailypolitical.com/2017/08/12/keel-point-llc-holds-position-in-amgen-inc-nasdaqamgn.html.
Several brokerages have recently weighed in on AMGN. UBS AG reaffirmed a “neutral” rating and set a $174.00 price target (down from $175.00) on shares of Amgen in a research note on Monday, May 22nd. Mizuho set a $195.00 price target on shares of Amgen and gave the stock a “buy” rating in a research note on Saturday, May 6th. Cowen and Company reaffirmed an “outperform” rating and set a $209.00 price target on shares of Amgen in a research note on Wednesday, April 19th. BMO Capital Markets reaffirmed a “buy” rating and set a $198.00 price target (down from $200.00) on shares of Amgen in a research note on Monday, May 22nd. Finally, Morgan Stanley raised their price target on shares of Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 13th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. Amgen presently has a consensus rating of “Buy” and a consensus target price of $186.64.
In other news, SVP Cynthia M. Patton sold 2,922 shares of the stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares in the company, valued at approximately $3,738,641.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.